Helminths (including anthelmintic resistance) roadmap:
Vaccines
Roadmap for the development of candidate vaccines for liver fluke
Download Liver-Fluke-Vaccine-Roadmap-1
---
config:
theme: default
defaultRenderer: 'elk'
themeVariables:
lineColor: "red"
---
flowchart LR
22001["
5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine9
Adjuvant5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
10
Expression system9
Adjuvant11
Vector7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
12
Identity of protective antigens9
Adjuvant12
Identity of protective antigens10
Expression system12
Identity of protective antigens11
Vector13
Identity of virulence factors12
Identity of protective antigens14
Identity of immunomodulators12
Identity of protective antigens15
Host responses to natural infection12
Identity of protective antigens15
Host responses to natural infection16
Identity of mechanisms of protection- AAntibody response
- BCell mediated immunity
16
Identity of mechanisms of protection- AAntibody response
- BCell mediated immunity
12
Identity of protective antigens17
Host pathogen interactions- AEntry
- BReplication
- CPersistence clearance
13
Identity of virulence factors17
Host pathogen interactions- AEntry
- BReplication
- CPersistence clearance
14
Identity of immunomodulators17
Host pathogen interactions- AEntry
- BReplication
- CPersistence clearance
15
Host responses to natural infection17
Host pathogen interactions- AEntry
- BReplication
- CPersistence clearance
18
Challenge model18
Challenge model1
Vaccine19
Pathogen genome17
Host pathogen interactions- AEntry
- BReplication
- CPersistence clearance
Lead Summary | Challenges and gap analysis | |
---|---|---|
1 | Vaccine | Vaccine giving long-lasting protection against infection by F. hepatica |
5D | Efficacy in challenge model | |
5C | Delivery platform | |
5B | Delivery route | |
5A | Safety | |
5 | DNA/RNA vaccines | Development of nucleic acid-based vaccines |
6D | Efficacy in challenge model | |
6C | Delivery platform | |
6B | Delivery route | |
6A | Safety | |
6 | Subunit vaccines | Development of subunit/peptide vaccine |
7D | Efficacy in challenge model | |
7C | Delivery platform | |
7B | Delivery route | |
7A | Safety | |
7 | Vectored vaccines | Development of a vectored vaccine |
9 | Adjuvant | Conventional and molecular Adjuvants |
10 | Expression system | Expression system for subunit vaccine |
11 | Vector | Vector identification for Vectored vaccine |
12 | Identity of protective antigens | Identity of Protective antigens |
13 | Identity of virulence factors | Identity of parasite virulence factors |
14 | Identity of immunomodulators | Identity of immunomodulators |
15 | Host responses to natural infection | Host response to natural infection |
16B | Cell mediated immunity | |
16A | Antibody response | |
16 | Identity of mechanisms of protection | Identify Mechanisms of protection against F. hepatica |
17C | Persistence clearance | |
17B | Replication | |
17A | Entry | |
17 | Host pathogen interactions | Host-parasite interactions |
18 | Challenge model | Challenge model |
19 | Pathogen genome | Bystander Immunoregulation |